Yantai Dongcheng Pharma Gains NMPA Approval for Sodium Fluoride [18F]

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has received marketing approval from the National Medical Products Administration (NMPA) for its sodium fluoride [18F]. This radiopharmaceutical imaging agent is used in positron emission tomography (PET) to identify regions of altered osteoblastic activity in bone imaging.

Product Mechanism
Sodium fluoride [18F] is a radiopharmaceutical imaging agent for positron emission tomography (PET). It is used to identify regions of altered osteoblastic activity in bone imaging. The fluoride [18F] ions in the injection undergo ion exchange with hydroxyl groups in bone hydroxyapatite crystals, forming fluoroapatite. This compound chemisorbs to bone tissue, enabling earlier and more sensitive detection of bone metastases.

Clinical Applications
Clinical trials have demonstrated the excellent diagnostic efficacy and favorable safety profile of sodium fluoride [18F]. It provides a valuable tool for informing personalized therapeutic strategies for patients with bone metastases.-Fineline Info & Tech